|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
JPRN |
|
Last refreshed on:
|
17 October 2023 |
|
Main ID: |
JPRN-UMIN000024289 |
|
Date of registration:
|
07/10/2016 |
|
Prospective Registration:
|
Yes |
|
Primary sponsor: |
|
|
Public title:
|
Association between telomere length and clinical indices in patients with idiopathic pulmonary fibrosis
|
|
Scientific title:
|
Association between telomere length and clinical indices in patients with idiopathic pulmonary fibrosis - Telomere length in idiopathic pulmonary fibrosis |
|
Date of first enrolment:
|
2016/11/24 |
|
Target sample size:
|
120 |
|
Recruitment status: |
Recruiting |
|
URL:
|
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000026900 |
|
Study type:
|
Observational |
|
Study design:
|
Not selected Not selected
|
|
Phase:
|
Not applicable
|
|
|
Countries of recruitment
|
|
Japan
| | | | | | | |
|
Contacts
|
|
Name:
|
Tomohiro
Handa |
|
Address:
|
54 Shougoin Kawahara-cho, Sakyo-ku, Kyoto, Japan
Japan |
|
Telephone:
|
075-751-3830 |
|
Email:
|
hanta@kuhp.kyoto-u.ac.jp |
|
Affiliation:
|
Graduate School of Medicine, Kyoto University Department of Respiratory Medicine |
|
|
Name:
|
Tomohiro
Handa |
|
Address:
|
54 Shogoin Kawahara-cho Sakyo-ku, Kyoto, Japan
606-8507
Japan |
|
Telephone:
|
075-751-3830 |
|
Email:
|
hanta@kuhp.kyoto-u.ac.jp |
|
Affiliation:
|
Graduate School of Medicine, Kyoto University Department of Respiratory Medicine |
| |
|
Key inclusion & exclusion criteria
|
Inclusion criteria:
Exclusion criteria: (A)Retrospective study; patients who experienced the onset of malignant disease within 3 years from first visit for our hospital. (B)Prospective study; (1) Patients with complication of malignant disease. But the patients who received complete resection or successful remission induction, and survived for more than 3 years without evidence of recurrence are eligible. (2) Patients who have been received more than 10mg/day of prednisolone or antifibrotic agents within 6 months. (3) Patients with acute exacerbation of IPF, respiratory infection, or pneumothorax within 4 weeks.
Age minimum:
20years-old
Age maximum:
Not applicable
Gender:
Male and Female
|
|
Health Condition(s) or Problem(s) studied
|
|
Idiopathic pulmonary fibrosis (IPF)
|
|
Primary Outcome(s)
|
|
Reduction in the telomere length attrition rate by administration of antifibrotic agent.
|
|
Source(s) of Monetary Support
|
|
Japan Science and Technology Agency
|
|
Ethics review
|
Status: YES
Approval date: 24/11/2016
Contact:
ethcom@kuhp.kyoto-u.ac.jp
Ethics Committe, Kyoto University Hospital and Kyoto University Graduate School and Faculty of Medicine
075-753-4680
ethcom@kuhp.kyoto-u.ac.jp
|
|
Results
|
|
Results available:
|
Yes |
|
Date Posted:
|
|
|
Date Completed:
|
23/05/2021 |
|
URL:
|
|
|
|